In February 2023, the CCCA sent a letter to the regulatory colleges of physicians, nurses, and pharmacists across Canada. The letter was in support of the approval of the repurposed drug ivermectin for the outpatient management of COVID-19. Currently, Paxlovid is approved for such treatment. It is high risk patients that most require early treatment, but many are not candidates for Paxlovid because of its potential drug interactions. In comparison to Paxlovid’s safety, effectiveness, and cost, Ivermectin is a viable, if not the only, option for these patients. We believe all Canadians should have the opportunity to access safe and effective therapies.
The letter to the regulatory colleges in Alberta is provided as an example.
To date, we have not received any meaningful reply from any of the colleges.